Skip to main content

Table 1 Characteristics of persons with and without Alzheimer’s disease on the index date (date of Alzheimer’s disease diagnosis or corresponding matching date for comparison persons)

From: Prevalence of oral anticoagulant use among people with and without Alzheimer’s disease

Total = 138 470

Alzheimer’s disease 68 609

No Alzheimer’s disease 69 861

P-Value

Gender

0.806

Women, N (%)

44 719 (65.2)

45 491(65.1)

 

Men, N (%)

23 890 (34.8)

24 370 (34.9)

 

Age (y), mean ± SD

80.0 ± 7.1

80.0 ± 7.1

0.49

Occupational social class

 < 0.001

Managerial/professional

14 329 (20.9)

15 059 (21.6)

 

Office

5 793 (8.4)

5 875 (8.4)

 

Farming/forestry

13 065 (19.0)

13 604 (19.5)

 

Sales/industrial/cleaning

29 203 (42.6)

27 181 (38.9)

 

Unknown

6 219 (9.1)

8 142 (11.7)

 

Anticoagulant use

 

 < 0.001

None

52 448 (76.4)

55 685 (79.7)

 

Oral

15 816 (23.1)

13 817 (19.8)

 

Parenteral

200 (0.3)

258 (0.4)

 

Both oral and parenteral

145 (0.2)

101 (0.1)

 

Oral anticoagulants and Oral antiplatelets

Warfarin

10 777 (15.7)

9 471 (13.6)

 < 0.001

Dipyridamolea

4 422 (6.4)

3 486 (5.0)

 < 0.001

Clopidogrel

1 055 (1.5)

1 185 (1.7)

0.019

Prasugrel

-b

0

N.Ac

Direct oral anticoagulants

Dabigatran

16 (0.02)

22 (0.03)

0.359

Rivaroxaban

15 (0.02)

28 (0.04)

0.054

Comorbidity

   

Atrial fibrillation

10 211 (14.9)

8 550 (12.2)

 < 0.001

Coronary artery bypass grafting

2 370 (3.5)

2 247 (3.2)

0.014

Percutaneous coronary intervention

1 626 (2.4)

1 831 (2.6)

0.003

Ischemic stroke

4 546 (6.6)

3 921 (5.6)

 < 0.001

Pulmonary embolism

925 (1.3)

948 (1.4)

0.88

Deep venous thrombosis

1 310 (1.9)

1 175 (1.7)

0.001

Hemorrhagic stroke

164 (0.2)

135 (0.2)

0.066

  1. aDipyridamole alone or in combination with acetylsalicylic acid
  2. bNumber of individuals < 5, exact number not reported to comply with restrictions regarding data reporting
  3. cN. A Not applicable